Screener
Sarepta Therapeutics, Inc. SRPT Treasury Stock
Treasury Stock at other companies
Other financials
Where this comes from
Reported directly by Sarepta Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:TreasuryStockValue.
The source filing: Sarepta Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335003
| Line item | As of June 30, 2026 | As of December 31, 2025 |
|---|---|---|
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value, 3,333,333 shares authorized; none issued and outstanding | — | — |
| Common stock, $0.0001 par value, 198,000,000 shares authorized; 106,279,142 and 105,623,500 issued and outstanding, respectively, at June 30, 2026 and 105,615,096 and 104,964,220 issued and outstanding, respectively, at December 31, 2025 | 11 | 11 |
| Treasury stock, at cost, 655,642 and 650,876 shares at June 30, 2026 and December 31, 2025, respectively | (25,263) | (25,263) |
| Additional paid-in capital | 6,104,530 | 6,042,586 |
| Accumulated other comprehensive (loss) income, net of tax | (565) | 272 |
| Accumulated deficit | (4,550,915) | (4,876,984) |
| Total stockholders’ equity | 1,527,798 | 1,140,622 |
Item 1. Financial Statements
FAQ
- What is Sarepta Therapeutics, Inc.'s treasury stock?
- Sarepta Therapeutics, Inc. (SRPT) reported treasury stock of $25.26M in Q2 2026.
- How has Sarepta Therapeutics, Inc.'s treasury stock changed year-over-year?
- Sarepta Therapeutics, Inc.'s treasury stock decreased by 0.0% year-over-year, from $25.26M to $25.26M.
- What does treasury stock mean?
- Shares repurchased by the company and held in treasury, reducing equity. Recorded at cost and presented as a negative equity component.
Ask your AI about Sarepta Therapeutics, Inc.'s treasury stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude